ReviewCurrent pain and headache reports2023
A Brief Review of Gepants.
Review in Current pain and headache reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- Functional near-infrared spectroscopy: Systematic mapping of abnormal brain function features in neurological disorders.Neural regeneration research · 2026Article
- Botulinum toxin for chronic migraine.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Intranasal Nano-Delivery Systems: Emerging Strategies for Central Nervous System Disease Therapeutics.International journal of nanomedicine · 2026Review
- CGRP and Migraine: Real-World Insights and Future Therapeutic Directions.Annual review of medicine · 2026Review
- Current Trends in Management of Migraine: A Review of Current Practice and Recent Advances.CNS & neurological disorders drug targets · 2026Review
- Expert consensus on gepants for acute and preventive treatment of migraine in Thailand.The journal of headache and pain · 2025Review
- GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of atogepant in migraine patients with multiple therapeutic failures.The journal of headache and pain · 2025Article
- Hallmarks of primary headache: part 1 - migraine.The journal of headache and pain · 2024Review
- Analyzing Google Search Trends for Migraine Surgery and Nurtec in Response to Public Announcements.Plastic and reconstructive surgery. Global open · 2024Article
- Migraine and Its Treatment from the Medicinal Chemistry Perspective.ACS pharmacology & translational science · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewGepants are small molecules that antagonize calcitonin gene-related peptide (CGRP) receptors. Due to their favorable side effect profile and versatility in treating headaches acutely and preventively, gepants are preferred over triptans. We will cover the indications for the four FDA-approved gepants in adults: rimegepant, atogepant, ubrogepant, and zavegepant. This review will illustrate how gepants will continue to revolutionize the acute and preventive treatment of headaches. RECENT
findingsGepants are now available in oral tablet, dissolving tablet, and intra-nasal spray formulations. Recent studies have shown promising utility in treating the pre-headache or prodromal phase. They have favorable tolerability, no evidence for association with medication overuse, and remain a safer alternative in those who have cerebrovascular risk factors. Additional research is needed to explore occurrence of Raynaud's phenomenon in participants treated with gepants, as it has been associated with CGRP monoclonal antibodies, but are not extensively studied in gepants. Gepants are expected to play a significant role in the next generation of migraine treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.